Co-operativity between the LdMetRS methionine and ATP binding sites is highlighted with the methionine K m varying depending on the ATP concentration used in the assay. (A) When ATP is used at a fixed, saturating concentration of 400 µM (10 x K m ), the methionine K m is shown to be 170 µM.
(B) However, if the fixed ATP concentration is reduced to 80 µM (2 x K m ), the methionine K m increases to 1500 µM. All data shown as mean ± SD (n=3 technical replicates).
[Methionine], µM three independent experiments. Average data from the three experiments: DDD806905 IC 50 1.68 µM (95% CI 1.00 -2.84 µM), Linezolid IC 50 15.1 µM (95% CI 7.8 -29.2 µM).
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SUPPLEMENTARY FIGURE 7: DDD806905 Leishmania Intracellular Amastigote EC 50 Determination
DDD806905 inhibits growth of Leishmania intracellular amastigotes with an EC 50 of 2.9 µM (95% CI 2.2 -3.9 µM) (n = 3 biological replicates). The representative potency determination shown returns a DDD806905 EC 50 of 2.8 µM and a Hill slope of 45 (data shown as mean ± SD, n=8 technical replicates).
[DDD806905], µM The maximum concentration in blood (C max ) was 2,600 ng/ml and 3,200 ng/ml for day 1 and day 10 respectively, T max was at 2h, AUC (0-8h) was 950,000 ng-min/ml on day 1 and 1,400,000 ng-min/ml on day 10.
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MATERIALS AND METHODS
LdMetRS Protein Expression and Purification
An E.coli codon optimised (Genscript) version of the LdMetRS gene (LdBPK_210890) was cloned into pET15b TEV vector using Nde1 and Xho1 restriction sites. The vector had been previously modified to include a HIS tag and TEV cleavage site at the N-terminus. The pellets were resuspended in 150 ml 20 mM HEPES, 500 mM NaCl, 5% Glycerol, 1 mM TCEP, 10
µM ZnCl 2 and 20 mM Imidazole pH 7.0 (Buffer A). DNAse I (Sigma) and protease inhibitors (Pierce)
were added. The cells were lysed using the Continuous Flow Cell Disrupter (Constant Systems) at 30 KPSI. The lysate was centrifuged at 40,000 g for 20 min and the supernatant was then filtered (0.2 µm).
The sample was loaded onto a 5 ml HiTrap His column (GE Healthcare) equilibrated with buffer A on an AKTA Purifier (GE). The column was then washed with 10 column volumes of buffer A. A step gradient of 5% Buffer B (A + 500 mM imidazole) was used to remove Histidine-rich protein contaminants. A gradient of 5 to 50% B over 20 column volumes was used to elute the LdMetRS.
The protein was then concentrated to 11 ml ready for gel filtration. Gel filtration was carried out on a Superdex 200 26/60 prep grade column (GE) in 20 mM HEPES, 500 mM NaCl, 5% Glycerol, 1 mM TCEP and 10 µM ZnCl 2 pH7.0. 10% glycerol was added for storage at -80 o C.
TbMetRS Protein Expression and Purification
A codon optimized gene encoding for TbMetRS (Uniprot ID Q38C91) was synthesized by GenScript (USA) for expression in E.coli. The gene encoded a truncated form of TbMetRS (residues 273-773) with three point mutations: K452A, K453R and E454A.
The gene was synthesized with an N-terminal His tag followed by a PreScission Protease cleavage site and cloned into a pET15b vector (Novagen) using NcoI and XhoI restriction sites.
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For expression, the plasmid was transformed into BL21 (DE3) cells by a standard heat shock method and plated onto LB agar containing 50 mg/ml carbenicillin. A single colony was used to inoculate a 100 ml starter culture that was grown overnight at 37 °C 200 rpm, prior to inoculating 6 l of autoinduction media. Cells were incubated for 4 h at 37 °C 200 rpm before the temperature was dropped to 22 °C and growth continued for a further 20 h. Cells were subsequently pelleted at 3,500 g 4 °C for 30 min and frozen until required.
The cell pellet was re-suspended in 3-4 pellet volumes of 25 mM HEPES, 500 mM NaCl, 10% Glycerol, 20 mM imidazole, 2 mM DTT pH7.0, Complete Protease Inhibitor Tablet (Roche) and DNase (0.1 mg/ml) before lysis on a Continuous Flow Cell Disrupter (Constant Systems).
Solid debris was removed by centrifugation at 40,000g for 20 min then filtered to 0.22 µm.
The sample was then loaded onto a 5 ml HiTrap HIS HP (GE) column pre equilibrated with 25 mM HEPES, 500 mM NaCl, 10% Glycerol, 20 mM imidazole, 2 mM DTT pH7.0 (Buffer A) using an AKTA Purifier system (GE) at 5 ml/min. The column was then washed for 10 column volumes with Buffer A.
A gradient of 0-50% B (A+500 mM imidazole) was used for the elution. At 5% B a His rich peak was eluted. At 6.8% B the gradient was held to elute the protein.
The protein was dialyzed overnight at 4 °C in Buffer A in the presence of PreScission Protease (PP) (5mg) before the sample was ran over 1 ml of Glutathione Sepharose 4B beads (GE) to remove the protease.
A second 5 ml HiTrap HIS HP (GE) column was performed to remove uncleaved protein before the sample was concentrated for gel filtration. The sample was run on a Superdex 200 26/60 column pre-equilibrated with 25 mM HEPES, 500 mM NaCl, 10% Glycerol, 2 mM DTT, 10 mM L-methionine pH7.0. Purified TbMetRS was concentrated to 10 mg/ml prior to crystallisation.
Size Exclusion Chromatography and Multi Angle Light Scattering (SEC-MALS)
SEC-MALS experiments were performed on a Dionex Ultimate 3000 HPLC system with an inline 
LdMetRS Assay Development and Kinetic Parameter Determinations
Activity of the LdMetRS enzyme was determined by monitoring levels of pyrophosphate released during the first step of the enzymatic reaction. The pyrophosphate formed was converted to two inorganic phosphate molecules using a pyrophosphatase enzyme and levels of the resulting phosphate molecules measured using the BIOMOL® Green reagent (Enzo Life Sciences) 2 .
Following optimization of the assay buffer and determination of the enzyme linearity, 384-well plate based assays were carried out at room temperature in a 50 μl reaction volume containing 30 mM All test compounds were solubilized in 100% DMSO to a concentration of 10 mM. To generate IC 50 data for the compounds, assay ready plates containing 10-point inhibitor curves (half-log serial dilutions) were prepared using an Echo® 550 (Labcyte).
Following preparation of the inhibitor curves, assays were carried out at room temperature in clear, flat bottom, polystyrene, 384-well plates (Greiner). Each assay was performed in a 50 μl reaction volume containing 30 mM Tris; pH 8.0, 140 mM NaCl, 30 mM KCl, 40 mM MgCl2, 0.01% (v/v) Brij-35, 1 mM DTT, 1 U/ml pyrophosphatase, 50 nM recombinant LdMetRS, 50 µM methionine and 100 µM ATP.
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Assays were performed by adding 25 μl buffer with enzyme to assay plates (with buffer only added to 'no enzyme' control wells) before the reaction was initiated with the addition of a 25 μl mix containing methionine, ATP and pyrophosphatase to all wells. Following a 120 min reaction at room temperature the assay was stopped with the addition of 50 μl BIOMOL® Green. The BIOMOL® Green signal was allowed to develop for 30 min before the absorbance of each well was read at 650 nm using an EnVision multilabel plate reader (PerkinElmer Life Sciences). All liquid dispensing steps were carried out using a Thermo Scientific WellMate dispenser (Matrix).
ActivityBase from IDBS (version 8.0.5.4) was used for data processing and analysis. All IC 50 curve fitting was undertaken using ActivityBase XE (version 7.7.1) from IDBS. A four-parameter logistic dose-response curve was utilized with prefit used for all four parameters. 
LdMetRS Mode of Inhibition Studies
To establish the mode of inhibition of DDD806905, data sets (generated using the BIOMOL® Green assay platform previously described) were collected by varying both the inhibitor and substrate concentrations. Using GraFit v6.0 (Erithacus Software) each data set was individually fitted to the Michaelis-Menten equation or the modified high substrate inhibition Michaelis-Menten equation described above (equation 2), and the resulting Lineweaver-Burk plots were examined for diagnostic patterns of competitive, mixed, or uncompetitive inhibition.
Data sets were then globally fitted to the appropriate model (with equations 4 and 5 used for competitive and mixed inhibition respectively). If more than one model appeared possible, then data were fitted to both and examined for significance using the F-test function in GraFit. Diffraction data were measured at Diamond Light Source beamline I02. Data were integrated using XDS 3 and scaled using Aimless 4 . Structure solution was carried out using MOLREP 5 with TbMetRS (4EGA) used as a search model. The structure was refined with REFMAC5 6 from the CCP4 suite 7 , ligand topologies generated using PRODRG 8 and manual model alteration carried out using COOT 9 .
S26 Equation 4 (Competitive inhibition equation):
Data measurement and model refinement statistics are presented in Supplementary Table 2 .
Coordinate files and associated experimental data have been deposited in the Protein Data Bank (PDB) with accession code 5NFH.
Leishmania tarentolae In Vitro Translation
Protein translation in a Leishmania cell extract was studied using a commercially available cell-free protein expression kit (Jena Bioscience). Reactions were carried out in black 384-well, small-volume plates (Greiner) in 10 µl reaction volumes containing 7 µl L. tarentolae cell extract, 1 µl eGFP DNA template and 2 µl nuclease free water ('no DNA' wells were included as negative controls). eGFP expression was monitored over time using a BMG PheraStar plate reader (Excitation 485 nm;
Emission 520 nm).
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When test compounds were to be screened, the compound of interest (solubilised in 100% DMSO) was dispensed into assay plates using an Echo® 550 (Labcyte) before L. tarentolae extract and eGFP template DNA were added to assay wells as described above. The reaction was run at room temperature for 120 min before eGFP fluorescence intensity was measured. IC 50 curve fitting was undertaken in GraFit version 6.0 (Erithacus Software) using a four-parameter logistic dose-response curve (equation 6), with s the slope. 
HeLa In Vitro Translation
Protein translation in a HeLa cell extract was studied using a commercially available in vitro translation kit (Thermo Scientific). Reactions were carried out in black 384-well, small-volume plates (Greiner) in 10 µl reaction volumes containing 5 µl HeLa cell extract, 1 µl accessory proteins, 2 µl reaction mix, 0.8 µl GFP DNA template and 1.2 µl nuclease free water ('no DNA' wells were included as negative controls). GFP expression was monitored over time using a BMG PheraStar plate reader (Excitation 485 nm; Emission 520 nm).
When testing DDD806905 and the positive control compound cycloheximide, compounds (solubilised in 100% DMSO) were dispensed into assay plates using an Echo® 550 (Labcyte) before HeLa extract, accessory proteins, reaction mix and GFP template DNA were added to assay wells and GFP expression monitored as described above.
Mitochondrial protein synthesis assay
The effect of DDD806905 on mitochondrial protein synthesis was determined by BioDuro using the MitoBiogenesisTM In-Cell ELISA Kit (Abcam). The kit reports the ratio of a nuclear (SDH-A) and a mitochondrially (COX-1) translated protein which is used to determine if there is a mitochondrial specific protein synthesis effect. In the assay the levels of SDH-A and COX-1 are measured in H9C2 cells. These are normalised to DMSO treated cells (vehicle) and then the ratio of normalised SDH-A over COX-1 is calculated. Dose response curves are calculated with this data and an IC 50 is reported. (50 mg/kg orally). Miltefosine was dosed once daily for 10 days, with vehicle and DDD806905 administered twice daily over the same interval. Drug dosing solutions were prepared fresh daily and the vehicle was 10% DMSO; 40% PEG400; 50% MilliQ water.
Mouse Pharmacokinetics (naive)
On day 19 post-infection, all animals were euthanized humanely and parasite burdens were determined microscopically on Rapi-Diff II liver smears. Parasite load is expressed in LeishmanDonovan Units (LDU) (mean number of amastigotes per 500 liver cell x mg weight of liver) 12, 13 .
Knock-out and overexpressor generation
Unsuccessful experiments to generate Leishmania MetRS knock-out or overexpressor cells were carried out following standard methods as described in 14 .
Leishmania Promastigote Assay
Compounds to be tested were pre-dispensed into white, clear bottom 384-well plates (Greiner). For potency determinations, ten-point one in three dilution curves were generated. The top concentration was 50 μM and on each plate a control curve of Amphotericin B was included. LdBOB promastigotes were added to all wells containing compound (5000 cells per well, 50μl) using a Thermo Scientific WellMate dispenser (Matrix). Media only was dispensed into control columns.
After a 68 h incubation at 37°C under 5% CO 2 in a humidified incubator, resazurin was added to each well at a final concentration of 0.5 mM and the plates were incubated for a further 4 h. Plates were then sealed with clear film and resorufin fluorescence was detected using a Victor 3 plate reader (Perkin Elmer) with excitation at 528 nm and emission at 590 nm. Serum shift experiments were S30 carried out as described above using 5%, 10% and 20% FBS in the media. To examine the effect of the methionine concentration on the potency of DDD806905 parasites were grown in the presence of drug and in the presence (or absence) of 20-fold excess methionine (0.3 g/l). IC 50 curve fitting was undertaken in GraFit version 6.0 (Erithacus Software) using a four-parameter logistic dose-response curve (equation 6), with s the slope.
Leishmania Axenic Amastigote Assay
The Leishmania axenic amastigote assay was performed using the method published in Nühs et al 15 .
Leishmania Intracellular Amastigote Assay
The intramacrophage Leishmania assay was performed using a modified version of the method described in De Rycker et al 16 . For potency determinations, ten-point, one in three dilution curves 
pK a measurements
To measure the pK a of DDD806905, a fast UV-metric method was performed using a Sirius T3 instrument (Sirius Analytical, U.K.). The calculation of the pK a was determined using the Sirius T3 refine software (Sirius Analytical, U.K.). In brief, the UV-metric pK a method is based on measuring pH during an acid-base titration and monitoring UV absorbance shift. The ionisation curve (Bjerrum curve) was then used to determine the pH where exactly 50 % of neutral and 50 % of ionised species was present. DDD806905 must be fully dissolved throughout the titration and so the titration is set to start at the pH where DDD806905 is in its fully ionised state. The appearance of precipitate was monitored throughout the experiment by a turbidity sensing device. DDD806905 was predicted to be poorly soluble (ACD labs) and so the titration was performed in the presence of methanol. The pK a s of DDD806905 was determined at the pH where there was maximal change in UV absorbance with respect to pH. The pH range of the titration was between 2 and 12. The pK a values were then extrapolated to an aqueous pK a using a graphical method based on the work by Yasuda and Shedlovsky 17, 18 using the Sirius T3 refine software 19 .
LogD 7.4 measurements
LogD 7.4 values were quantified using a Sirius T3 instrument (Sirius Analytical, U.K.). The lipophilicity assay was a standard potentiometric titration performed in the presence of three varying octanolwater ratios. The instrument software calculated the pH of each data point using mass and charge balance equations and then fitted this theoretical data to the experimental data. The logP value S32 which gave the best fit to the data was then recorded as the logP. Using the logP and an experimentally determined pK a (see above), the software generated a lipophilicity plot showing changes in the logD with increasing pH and from this plot a logD 7.3 and logD 5.6 values were recorded.
Plasma Protein Binding Determination
A 96-well equilibrium dialysis apparatus was used to determine the free fraction in plasma for The unbound fraction (fu) was determined as the ratio of the peak area in buffer to that in plasma.
Medicinal Chemistry
All compounds in Supplementary Table 1 provided by GSK. Table 1 . 
Preparation of compounds in
Preparation of 2-((3-(((
4
Preparation of intermediate 4,6-dichloro-1H-indole-2-carbaldehyde:
A solution of ethyl 4,6-dichloro-1H-indole-2-carboxylate (4.0 g, 15.5 mmol) in THF (100 mL) at 0°C was treated dropwise with LiAlH 4 (2 M in THF) (16.0 mL, 32.0 mmol). The reaction was then slowly allowed to warm to room temperature and stirred for 18 h before being carefully quenched by the careful dropwise addition of 3 mL of 2 M sodium hydroxide solution, followed by 100 mL of potassium sodium tartrate solution. The reaction mixture was stirred for 30 min prior to dilution with diethylether (100 mL) and stirring for 1 h before removal of the organic phase and extraction of the aqueous phase with diethylether (3 x 50 mL). The combined organic extracts were dried (MgSO 4 ), filtered and concentrated in vacuo. Chromatography (SiO 2 , 50 to 100% EtOAc : hexanes)
gave (4,6-dichloro-1H-indol-2-yl)methanol (2.50 g, 11.57 mmol, 65%). This was immediately dissolved in DCM (250 mL) and treated portionwise with manganese dioxide (5.03 g, 57.9 mmol) at room temperature and the reaction stirred overnight at 40°C. The reaction was allowed to cool prior to filtration through a short pad of celite. The celite was washed with ether (200 mL) and the filtrate concentrated in vacuo to the title compound (2.39 g, 11.0 mmol, 95%) as a fluffy off-white powder.
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Preparation of 2-((3-(((4,6-dichloro-1H-indol-2-yl)methyl)amino)propyl)amino)quinazolin-4(1H)-one dihydrochloride (DDD806905.2HCl):
A slurry of 2-(3-aminopropylamino)-3H-quinazolin-4-one (2.39 g, 11.0 mmol) and 4,6-dichloro-1H-indole-2-carbaldehyde (2.39 g, 11.2 mmol) in THF (250 mL) at room temperature needed to be warmed to 55°C in order to obtain a solution. After stirring at 55°C for 60 mins sodium triacetoxyborohydride (4.75 g, 22.4 mmol) was added portionwise and the resulting solution was stirred for 72 h. The reaction was then cooled to room temperature then quenched by careful addition of 25 mL NaOH solution. The reaction was then diluted with brine (100 mL) and diethylether (100 mL) and stirred for 2 h, the organic phase separated, combined with organic extracts of the aqueous layer (3 x 50 mL EtOAc), the combined organics dried (MgSO 4 ) and concentrated in vacuo. The residual gum was subjected to chromatography (SiO 2 , 100% EtOAc moving to 20% 7 N methanolic ammonia in EtOAc) to give 1.85 g of the title compounds as the free base. This solid was then slurried in dry diethylether and treated dropwise with 1 M HCl in diethylether and the resulting precipitate collected by filtration and dried to give the title compound After stirring at RT for 3 h, complete consumption of starting material was noted and the reaction mixture was partitioned between 2N NaOH (10 mL) and EtOAc (20 mL), a precipitate formed at this point which was filtered off. LC/MS and NMR analysis of the precipitate showed it not to be product.
The aqueous layer was further extracted with EtOAc (2 × 20 mL) and the combined organics were washed with brine, dried over MgSO4 and concentrated. 1 H NMR of the crude reaction mixture showed it to be composed mostly of desired product. The residue was dry-loaded onto silica and purified by column chromatography (SiO 2 , 100% EtOAc moving to 10% 7 N methanolic ammonia in EtOAc) to give the title compound as a yellow oil. and the reaction was stirred at room temperature overnight. LC/MS showed formation of some product, however reaction very messy. The reaction mixture was partitioned between 2N NaOH (10 mL) and EtOAc (20 mL). The aqueous layer was further extracted with EtOAc (2 × 20 mL) and the combined organics were washed with brine (20 mL), dried over MgSO 4 and concentrated in vacuo.
The crude residue was dry-loaded onto silica and purified by column chromatography (SiO 2 0-100% gradient of 10% MeOH/EtOAc in heptane) to give fractions containing the desired product, however impurities still present. All the fractions containing product were combined and the solvent removed in vacuo. 
